Sugi Predict

Sugi Predict / Compounds / SCHEMBL14769319

SCHEMBL14769319

SCHEMBL14769319

CS(=O)(=O)OCCOCCOc1ccc(Nc2ncc(F)c(Nc3cccc(N)c3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 12/20 0.59
▸ EGFR P00533 8/20 0.59
▸ ITK Q08881 4/20 0.59
▸ BTK Q06187 2/20 0.56
▸ JAK2 O60674 2/20 0.56
▸ LYN P07948 2/20 0.56
▸ JAK3 P52333 2/20 0.56
▸ TEC P42680 1/20 0.56
▸ TXK P42681 1/20 0.56
▸ BMX P51813 1/20 0.56
▸ CD69 Q07108 1/20 0.56
▸ PLK4 O00444 1/20 0.51
▸ AURKA O14965 1/20 0.51
▸ PDPK1 O15530 1/20 0.51
▸ DAPK3 O43293 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ PAK4 O96013 1/20 0.51
▸ CHEK2 O96017 1/20 0.51
▸ ERBB2 P04626 1/20 0.51
▸ NTRK1 P04629 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13166672 0.91 EGFR (0.59) SYKEGFRITKBTKJAK2
SCHEMBL18737417 0.88 SYK (0.67) SYKEGFRITKBTKJAK2
SCHEMBL13166664 0.86 SYK (0.67) SYKEGFRITKBTKJAK2
SCHEMBL13166285 0.85 SYK (0.77) SYKEGFRITKBTKJAK2
SCHEMBL29665636 0.85 SYK (0.77) SYKEGFRITKBTKJAK2
SCHEMBL27020093 0.85 SYK (0.77) SYKEGFRITKBTKJAK2
SCHEMBL18737587 0.84 ITK (0.65) SYKEGFRITKBTKJAK2
SCHEMBL22909131 0.84 SYK (0.70) SYKEGFRITKBTKJAK2
SCHEMBL15814664 0.82 SYK (0.66) SYKEGFRITKBTKJAK2
SCHEMBL14769318 0.82 EGFR (0.74) SYKEGFRITKBTKJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10010548-B2 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE CAR LLC (BM) 2018-07-03 — — US disclosed
US-10010548-B2 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE CAR LLC (BM) 2018-07-03 — — US disclosed
US-20170100397-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-04-13 — — US disclosed
US-20170100397-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-04-13 — — US disclosed
US-9409921-B2 2,4-disubstituted pyrimidines as kinase inhibitors CELGENE AVILOMICS RESEARCH, INC. (US) 2016-08-09 — — US disclosed
US-9409921-B2 2,4-disubstituted pyrimidines as kinase inhibitors CELGENE AVILOMICS RESEARCH, INC. (US) 2016-08-09 — — US disclosed
US-8710222-B2 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE AVILOMICS RESEARCH, INC. (US) 2014-04-29 — — US disclosed
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2013-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10010548-B2 2,4-disubstituted pyrimidines useful as kinase inhibitors DCK, CDK2, DTYMK SYK 610/4885EGFR 460/4885ITK 317/4885
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 SYK 2370/4885EGFR 1981/4885ITK 2697/4885
US-20170100397-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 SYK 2370/4885EGFR 1981/4885ITK 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.